| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/25/2004 | US20040058984 Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans |
| 03/25/2004 | US20040058951 Integrin targeted imaging agents |
| 03/25/2004 | US20040058896 Uniform dispersion in excipient of fatty acid, triglyceride and,or fatty ester |
| 03/25/2004 | US20040058895 Administering by injection; reduction of blood parathyroid hormone |
| 03/25/2004 | US20040058884 Detecting diseases by Selex method; anticancer agents |
| 03/25/2004 | US20040058859 Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
| 03/25/2004 | US20040058857 Mixture of glucocorticoids and prostate specific antigen, or complex thereof; anticancer agents |
| 03/25/2004 | US20040058854 Synergistc therapy; bioavailability |
| 03/25/2004 | US20040058168 For tinting a polymer |
| 03/25/2004 | US20040058022 Method for producing fat and /or solids from beans and compositions containing polyphenols |
| 03/25/2004 | US20040058018 Novel substituted benzimidazole dosage forms and method of using same |
| 03/25/2004 | US20040058008 For reducing aggregation; encapsulated by polyanhydrides |
| 03/25/2004 | US20040058005 Comprises polyvinylpyrrolidone; for improved bioavailability/ dissolution |
| 03/25/2004 | US20040058004 Suspensions of micronized fenofibrate |
| 03/25/2004 | US20040058002 Expandable osmotic composition and coating suspension |
| 03/25/2004 | US20040058001 For controlled release; drug delivery |
| 03/25/2004 | US20040058000 Controlled release capsule for delivery of liquid formulation |
| 03/25/2004 | US20040057999 Fenofibrate compositions having enhanced bioavailability |
| 03/25/2004 | US20040057998 Granulates of micronized fenofibrate; high bioavailability through improved dissolution |
| 03/25/2004 | US20040057997 Capsules containing fenofibrate compositions |
| 03/25/2004 | US20040057996 Initial release of the bioactive substance is suppressed; matrix containing a bioactive substance and a cationic substance (e.g. benzalkonium chloride or lysine) and/or a polyol such as polyethylene glycol |
| 03/25/2004 | US20040057992 6-phenyl-5-(4-(2-pyrrolidin-1-ylethoxy)phenyl)-5,6,7,8 -tetrahydronaphthalen-2-ol (laxofoxifene); a prodrug with a glidant, disintegrant, lubricant and diluent/filler in given amounts; unit dosage forms, including low dosage forms |
| 03/25/2004 | US20040057991 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| 03/25/2004 | US20040057990 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 03/25/2004 | US20040057987 With a permeation enhancer or mixture such as myristyl sarcosine; treatment of acute renal failure |
| 03/25/2004 | US20040057985 With sufficient release rates without needing any enhancer; oxybutynin of the droplet-shaped inner phase will not accumulate at the interfaces and surfaces of the matrix layer if certain polymers are used as pressure sensitive adhesive |
| 03/25/2004 | US20040057979 Methods for treating inflammation-mediated conditions of the eye |
| 03/25/2004 | US20040057972 By adjusting the pH of the composition to between 6.5 and about 8.1 |
| 03/25/2004 | US20040057962 Immunogenic complex |
| 03/25/2004 | US20040057952 Where antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid; methods for detection, monitoring and treatment of cancer |
| 03/25/2004 | US20040057946 Forming a solution of protein encapsulated, insoluble gas-filled microbubbles conjugated to biological agent; administering solution to animal; so that protein directs microbubble-conjugated agent to sites of bioprocessing |
| 03/25/2004 | US20040057940 Imaging and targeting tumors using sickle cells |
| 03/25/2004 | US20040057928 Use of IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for manufacture of medicament for therapy and/or prophylaxis |
| 03/25/2004 | US20040057927 Formulations for IL-11 |
| 03/25/2004 | US20040057922 For use as foaming agents |
| 03/25/2004 | US20040057907 Dri-nasal sprays |
| 03/25/2004 | US20040057900 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 03/25/2004 | US20040057899 Stabilised radiopharmaceutical compositions |
| 03/25/2004 | US20040056372 Stabilizing a high concentrate drug content in water, by dissolving the drug and a polyetheramide copolymer in solvent, forming water in oil emulsion, volatilizing, desolventizing, supersonic treatment and ultrafiltration |
| 03/25/2004 | DE10242088A1 Controlled release medicament, e.g. for parenteral administration of flupirtine, comprising drug, sucrose acetate-isobutyrate and mixture of solvents miscible and immiscible with sucrose acetate-isobutyrate |
| 03/25/2004 | DE10242076A1 New covalently bonded conjugates of hydroxyalkyl starch with allergens, useful as modified allergens with depot effect for use in specific immunotherapy for combating allergies, e.g. hay fever |
| 03/25/2004 | CA2799437A1 Method of producing hydroxyalkyl starch derivatives |
| 03/25/2004 | CA2499214A1 Stable immunogenic product comprising antigenic heterocomplexes |
| 03/25/2004 | CA2499075A1 Production of bispecific molecules using polyethylene glycol linkers |
| 03/25/2004 | CA2498502A1 Recombinant clostridial toxin fragments with proteolytic activation |
| 03/25/2004 | CA2496318A1 Hydroxyalkyl starch derivatives |
| 03/25/2004 | CA2496317A1 Method of producing hydroxyalkyl starch derivatives |
| 03/25/2004 | CA2495242A1 Hasylated polypeptides, especially hasylated erythropoietin |
| 03/24/2004 | EP1400579A2 Composition with anti-oxidative properties |
| 03/24/2004 | EP1400550A1 Branched polyalkylene glycols |
| 03/24/2004 | EP1400533A1 HASylated polypeptides, especially HASylated erythropoietin |
| 03/24/2004 | EP1400249A1 Pharmaceutical preparation of diclofenac sodium |
| 03/24/2004 | EP1400248A1 Process for sterilization of protein containing biological compositions |
| 03/24/2004 | EP1399850A2 Hla ligand database utilizing predictive algorithms and methods of making and using same |
| 03/24/2004 | EP1399570A2 Peptides for use as translocation factors |
| 03/24/2004 | EP1399531A1 Methods and formulations for enhancing the dissolution of a solid material in liquid |
| 03/24/2004 | EP1399501A1 Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug |
| 03/24/2004 | EP1399499A1 Agent for the prevention and treatment of sexually transmitted diseases-i |
| 03/24/2004 | EP1399482A2 Determination of bone-sialoprotein in bodily fluids for oncological problems |
| 03/24/2004 | EP1399467A2 Peptide deformylase activated prodrugs |
| 03/24/2004 | EP1399309A1 Method and device for producing compression coated tablets |
| 03/24/2004 | EP1399215A2 Tissue-specific endothelial membrane proteins |
| 03/24/2004 | EP1399192A1 Conjugates of polysaccharide polymers of natural origin |
| 03/24/2004 | EP1399191A2 Cell penetrating therapeutic agents |
| 03/24/2004 | EP1399190A1 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| 03/24/2004 | EP1399189A1 Compositions and methods for enhancing nucleic acid transfer into cells |
| 03/24/2004 | EP1399187A2 Uses of monoclonal antibody 8h9 |
| 03/24/2004 | EP1399170A2 Chelates of metals which can be activated by neutrons and their use for the measurement of labeled specimens |
| 03/24/2004 | EP1399169A1 Exothermic formulations for the treatment of ectoparasites |
| 03/24/2004 | EP1399168A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 03/24/2004 | EP1399165A2 Stabilized dispersion of phytosterol in oil |
| 03/24/2004 | EP1399161A2 Sustained-release analgesic compounds |
| 03/24/2004 | EP1399153A2 Pharmaceutical composition comprising a drug and a fatty acid or salt thereof |
| 03/24/2004 | EP1399152A1 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester |
| 03/24/2004 | EP1399149A2 Taxane prodrugs |
| 03/24/2004 | EP1399147A2 Therapeutic delivery of carbon monoxide |
| 03/24/2004 | EP1399131A2 Spray freeze-dried compositions |
| 03/24/2004 | EP1399130A1 Emulsion and dispersion formulations and method |
| 03/24/2004 | EP1399129A1 Compositions with controlled release of lactic acid at vaginal level |
| 03/24/2004 | EP1399128A1 Composition for the treatment of diseases which affect animals' hooves |
| 03/24/2004 | EP1399127A1 Olopatadine formulations for topical administration |
| 03/24/2004 | EP1399119A2 Oral compositions and use thereof |
| 03/24/2004 | EP1399108A2 Preparation of a therapeutic composition |
| 03/24/2004 | EP1399105A2 Method for cleaning hard gelatine capsules |
| 03/24/2004 | EP1399034A1 Taste modifiers comprising a chlorogenic acid |
| 03/24/2004 | EP1399032A1 Improved hard sugar coating method |
| 03/24/2004 | EP1301176B1 Method for coating solid particles with a thermofusible agent, and resulting coated solid particles |
| 03/24/2004 | EP1292606A4 Positively-charged peptide nucleic acid analogs with improved properties |
| 03/24/2004 | EP1242087B1 Analgesic compositions containing buprenorphine |
| 03/24/2004 | EP1150820B1 Injection molding method for neutral and acidic-group containing (meth)acrylate copolymers |
| 03/24/2004 | EP1128816B1 Polyvinyl alcohol microspheres, and methods for making of the same |
| 03/24/2004 | EP1121456A4 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 03/24/2004 | EP0948318B1 Granulates comprising a water soluble compound and cellulose |
| 03/24/2004 | EP0795015B1 Plasmids suitable for il-2 expression |
| 03/24/2004 | EP0784469B1 Compositions for the delivery of antigens |
| 03/24/2004 | EP0781134B1 Scopolamine plaster |
| 03/24/2004 | CN1484649A Stabilized pharmaceutical composition in lyophilized form |
| 03/24/2004 | CN1484534A Stabilised radiopharmaceutical composition |
| 03/24/2004 | CN1484532A Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
| 03/24/2004 | CN1484528A Pharmaceutical composition comprising wikstromol and/or mataires inal, its use as hepatoprotectant and process for their isolation from cedurs deodara |